NM_032043.3:c.2071A>C
Variant summary
Our verdict is Uncertain significance. Variant got 0 ACMG points: 0P and 0B.
The NM_032043.3(BRIP1):c.2071A>C(p.Ile691Leu) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000124 in 1,613,980 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Uncertain significance (★★).
Frequency
Consequence
NM_032043.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 0 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000131 AC: 2AN: 152140Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000239 AC: 6AN: 251368Hom.: 0 AF XY: 0.0000221 AC XY: 3AN XY: 135842
GnomAD4 exome AF: 0.0000123 AC: 18AN: 1461840Hom.: 0 Cov.: 31 AF XY: 0.0000138 AC XY: 10AN XY: 727226
GnomAD4 genome AF: 0.0000131 AC: 2AN: 152140Hom.: 0 Cov.: 32 AF XY: 0.0000135 AC XY: 1AN XY: 74318
ClinVar
Submissions by phenotype
not provided Uncertain:3Other:1
Variant interpreted as Uncertain significance and reported on 07-14-2015 by Lab Ambry Genetics. GenomeConnect-Invitae Patient Insights Network assertions are reported exactly as they appear on the patient-provided report from the testing laboratory. Registry team members make no attempt to reinterpret the clinical significance of the variant. Phenotypic details are available under supporting information. -
PS3_supporting -
In the published literature, this variant has been reported in individuals with breast cancer (PMID: 26921362 (2016), 26976419 (2016), 31822495 (2020)), ovarian cancer (PMID: 31822495 (2020)) as well as in unaffected individuals (PMID: 26315354 (2015)). Published functional studies show that this variant leads to reduced protein stability and partial loss of protein function (PMID: 31822495 (2020)). The frequency of this variant in the general population, 0.000035 (4/113678 chromosomes (Genome Aggregation Database, http://gnomad.broadinstitute.org)), is uninformative in the assessment of its pathogenicity. Analysis of this variant using bioinformatics tools for the prediction of the effect of amino acid changes on protein structure and function yielded predictions that this variant is damaging. Based on the available information, we are unable to determine the clinical significance of this variant. -
Published functional studies demonstrate the ability to partially repair interstrand crosslinks possibly resulting in a hypomorphic allele (PMID: 31822495); Observed in individuals with breast and/or ovarian cancer but also in healthy controls (PMID: 26921362, 31822495, 26315354, 26976419); In silico analysis indicates that this missense variant does not alter protein structure/function; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 26976419, 26315354, 26921362, 31822495, 11301010) -
Hereditary cancer-predisposing syndrome Uncertain:3
- -
The p.I691L variant (also known as c.2071A>C), located in coding exon 13 of the BRIP1 gene, results from an A to C substitution at nucleotide position 2071. The isoleucine at codon 691 is replaced by leucine, an amino acid with highly similar properties. This variant has been identified individuals with breast and ovarian cancer as well as unaffected controls (Tung N et al. J. Clin. Oncol. 2016 May;34(13):1460-8; Easton DF et al. J. Med. Genet., 2016 05;53:298-309; Moyer CL et al. Cancer Res. 2020 Feb;80:857-867; Ramus SJ et al. J. Natl. Cancer Inst. 2015 Nov;107(11)). Based on results from an inter-strand cross link damage survival assay, this variant was characterized as hypomorphic by one group (Moyer CL et al. Cancer Res. 2020 Feb;80:857-867). This amino acid position is well conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Based on the available evidence, the clinical significance of this variant remains unclear. -
This missense variant replaces isoleucine with leucine at codon 691 in the helicase domain of the BRIP1 protein. Computational prediction suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.5, PMID: 27666373). A functional study has reported that this variant does not impact BRIP1 function in a sensitivity assay to mitomycin C and it does decrease protein stability (PMID: 31822495). This variant has been observed in over 10 individuals affected with breast and/or ovarian cancer (PMID: 26921362, 26976419, 31822495) and in one unaffected individuals from an ovarian cancer case-control study (PMID: 26315354). This variant has also been identified in 6/251368 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. -
Familial cancer of breast Uncertain:2
This variant is classified as a variant of uncertain significance as there is insufficient evidence to determine its impact on protein function and/or cancer risk. -
- -
not specified Uncertain:1
- -
Familial cancer of breast;C1836860:Fanconi anemia complementation group J Uncertain:1
This sequence change replaces isoleucine, which is neutral and non-polar, with leucine, which is neutral and non-polar, at codon 691 of the BRIP1 protein (p.Ile691Leu). This variant is present in population databases (rs587782356, gnomAD 0.004%). This missense change has been observed in individual(s) with breast and/or ovarian cancer (PMID: 26921362, 26976419, 31822495). ClinVar contains an entry for this variant (Variation ID: 142280). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is not expected to disrupt BRIP1 protein function with a negative predictive value of 95%. Experimental studies have shown that this missense change affects BRIP1 function (PMID: 31822495). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
Fanconi anemia complementation group J Uncertain:1
- -
Ovarian neoplasm Uncertain:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at